APA

Melief S. M., Visconti V. V., Visser M., van Diepen M., Kapiteijn E. H. W., van den Berg J. H., Haanen J. B. A. G., Smit V. T. H. B. M., Oosting J., van der Burg S. H. & Verdegaal E. M. E. (20171122). Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature. : Cancer immunology research.

Chicago

Melief Sara M, Visconti Valeria V, Visser Marten, van Diepen Merel, Kapiteijn Ellen H W, van den Berg Joost H, Haanen John B A G, Smit Vincent T H B M, Oosting Jan, van der Burg Sjoerd H and Verdegaal Els M E. 20171122. Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature. : Cancer immunology research.

Harvard

Melief S. M., Visconti V. V., Visser M., van Diepen M., Kapiteijn E. H. W., van den Berg J. H., Haanen J. B. A. G., Smit V. T. H. B. M., Oosting J., van der Burg S. H. and Verdegaal E. M. E. (20171122). Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature. : Cancer immunology research.

MLA

Melief Sara M, Visconti Valeria V, Visser Marten, van Diepen Merel, Kapiteijn Ellen H W, van den Berg Joost H, Haanen John B A G, Smit Vincent T H B M, Oosting Jan, van der Burg Sjoerd H and Verdegaal Els M E. Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature. : Cancer immunology research. 20171122.